Literature DB >> 6848603

5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells.

E Lotzová, C A Savary, D A Stringfellow.   

Abstract

We tested the effect of three different interferon-(IFN) inducing pyrimidinone molecules with cancer therapeutic potential on natural killer (NK) cells. Peritoneal exudate (PE) cells were selected for these studies because their NK cell cytotoxicity is very low. Augmentation of PE-NK cell cytotoxicity was observed in eight different strains of mice after i.p. administration of 250 mg/kg of each of the pyrimidinones. NK cell induction occurred as early as 6 hr after pyrimidinone administration and peaked 2 to 4 days after treatment; at that time, cytotoxicity was as high as 60 to 90%. Augmentation of NK cell activity was independent of IFN serum levels induced by pyrimidinones and murine H-2 haplotype, and did not exhibit any histocompatibility or species-specific restriction, because it was expressed to syngeneic, allogeneic, and xenogeneic tumor target cells. Characterization studies demonstrated that the cytolytic cells were not macrophages, T cells, or B cells and exhibited NK cell characteristics. NK cell tumor-binding and tumor-killing studies demonstrated that NK cell augmentation was accomplished via both activation and recruitment of NK cells. If one considers NK cells as an important part of tumor immunity (as indicated by murine studies), pyrimidinone molecules may be effective anticancer agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Pyrimidinone (bropirimine) mediated alteration of T lymphocyte subsets during murine cytomegalovirus infection.

Authors:  R J Brideau; J A Nicholas
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

Review 3.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Effect of pyrimidinone treatment on lethal and immunosuppressive murine cytomegalovirus infection.

Authors:  R J Brideau; J A Wolcott
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

5.  Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Depression of murine natural killer cell cytotoxicity by isobutyl nitrite.

Authors:  E Lotzová; C A Savary; E M Hersh; A A Khan; M Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Studies on the antitumor activities of pyrimidinone-interferon inducers. Part 2. Potentiation of antitumor resistance mechanisms.

Authors:  L Milas; N Hunter; H Ito; E Lotzová; D A Stringfellow
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

8.  In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases.

Authors:  M S Roh; M P Kahky; C Oyedeji; J Klostergaard; L Wang; S A Curley; E Lotzová
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

10.  Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract.

Authors:  E Lotzová; C A Savary; R S Freedman; J M Bowen
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.